CURE continues to be an important supporter of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Winship Cancer Institute at Emory University as well as other leading pediatric cancer research institutions across the nation. Through generosity of donors, CURE is able to provide nearly $4 million in annual support to promising research projects.

In the past 12 years, CURE Childhood Cancer has contributed more than $25 million to research aimed at finding safer and more effective treatments for cancers that affect children. For the current fiscal year, we are funding 15 specific projects, including continued support of the Aflac Cancer Center Precision Medicine Program which envisions personalized, non-toxic and curative cancer therapy for all children.

In addition to the Precision Medicine Program is funding research at centers of excellence around the country.

Research Projects

Fellowship Program

AFLAC Cancer & Blood Disorders, Emory University

 

Douglas Graham MD, PhD

Aflac Cancer Center Precision Medicine Program

Kavita Dhodapkar, MD

Precision Cellular Immunotherapy of High-risk Glioma in Children

Kelly Goldsmith, MD

Optimizing Chemoimmunotherapy with DFMO in Relapsed and Refractory Neuroblastoma

Lisa Ingerski, PhD

Health Related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of Refractory or Progressive Pediatric Brain Tumors

Tobey MacDonald, MD

Employing Focused Ultrasound to Aid Therapeutic Delivery to Pediatric Brain Tumors

Tobey MacDonald, MD

Phase I Trial of WP1066 in Children with Refractory and Progressive Malignant Brain Tumors with Evidence of JAK2/STAT3 Pathway Activation

Robert Schnepp, MD, PhD

BMI1 as an Oncogenic Driver and Novel Target in Alveolar Rhabdomyosarcoma

Lubing Gu, MD

Development of Dual Inhibitors of MDM2 and XIAP for Treatment of Childhood Cancers

Children’s Oncology Group & Fred Hutchinson Cancer Research Center

 

Soheil Meshinchi, MD, PhD

Target Pediatric AML

Children’s Cancer Therapy Development Institute

 

Charles Keller, MD

Prediction & Validation of a Novel Drug Combination Against Anaplastic Wilms’ tumor

Baylor College of Medicine

 

Alexandra Stevens, MD

A Trial of Atovaquone with Conventional Chemotherapy for Pediatric AML (ATACC AML)

Lisa L. Wang, MD

Optimizing GD2.CAR T Cell Immunotherapeutic Strategies for Relapsed Osteosarcoma and Neuroblastoma

The Children’s Hospital of Philadelphia

 

Frank M. Balis, MD

GD2 as a Circulating Tumor Biomarker and Clinical Trial Endpoint for Neuroblastoma

Michael Chorny, PhD

Targeted Neuroblastoma Pharmacotherapy Using Nanocarriers

 

Join Our Newsletter

Subscribe